Legend Biotech (LEGN) Common Equity (2019 - 2025)

Legend Biotech (LEGN) has reported Common Equity for 7 consecutive years, with $1.0 billion the latest figure, recorded in Q4 2025.

• Quarterly Common Equity fell 3.7% year-over-year to $1.0 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 billion (down 3.7% YoY) and the FY2025 annual result came in at $1.0 billion, down 3.7% from the prior year.
• Common Equity slipped to $1.0 billion in Q4 2025 per LEGN's latest filing, from $1.0 billion in the prior quarter.
• Over the last five years, Common Equity for LEGN reached as high as $1.4 billion in Q2 2023 and fell as low as $206451.0 in Q1 2021.
• A 5-year average of $870.9 million and a median of $1.0 billion in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity slumped 99.92% — and 2022, when it jumped 358900.44%.
• Year by year, Common Equity stood at $765.9 million in 2021, then retreated by 2.82% to $744.3 million in 2022, then soared by 68.12% to $1.3 billion in 2023, then fell by 16.84% to $1.0 billion in 2024, then decreased by 3.7% to $1.0 billion in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $1.0 billion, $1.0 billion, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.